Skip to content

Canada – EN logo

Main menu
    • About us
    • Our mission, vision & values
    • HER Professional Journey
    • Our leaders
    • Transparency
    • Environmental, Social & Governance
    • Diversity, equity, inclusion & belonging
  • Our products
  • Media
  • Join our team

Contact us

Visit Organon's LinkedIn Opens a new window

Back
Change Language
  • Français
Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Rui Mesquita

Country Medical Lead, Medical Affairs

Download Photo

Follow on LinkedIn

Rui Mesquita, MD PhD, Medical Director at Organon Canada, leads the Medical Affairs team, developing value-added medical affairs activities in partnership with healthcare experts and other relevant stakeholders. He and his team work everyday to seek relevant clinical and scientific insights, fill data gaps through local data generation, answer medical information requests and develop innovative medical education tools and initiatives.

Through his 18 year pharma-industry career, Rui has gained experience and expertise in a variety of therapeutical areas, as well as in diverse pharma company functions. In his previous role, Rui has served as Medical Lead for Organon Portugal. Before joining Organon, Rui worked at Merck and Bristol Myers Squibb where he developed expertise and experience in clinical studies management, field medical science, medical education, and partnership projects with multiple types of healthcare stakeholders.

Rui is a passionate team leader who believes that his main role is to help his team members to perform by leveraging their strengths, enabling their cross functional collaboration and helping them to balance their work and life.

Rui holds a master’s in medicine by Lisbon Medical School, a PhD in Medicine by King’s College London and an executive MBA from Católica and Nova Lisbon Business Schools. Additionally, he holds a certificate in Value-Based Healthcare by Harvard Business School.

On the personal side, Rui is married to Sofia, and they are parents of two boys, Tomas and Diogo.

  CA-NON-110409

Connect with us on social

Linkedin icon Opens a new window
Canada – EN logo

Company

  • About us
  • Our mission, vision & values
  • Her Professional Journey
  • Our leaders

Resources

  • Our products
  • Media

Contact information

  • Contact us
  • Join our team
  • Cookie Policy
  • Privacy Notice
  • Terms of Use
  • Terms and Conditions for Sales
  • Community Engagement Guidelines
  • Statement of Organon on Forced Labour
  • Sitemap
© 2025 Organon group of companies. All rights reserved.
CA-NON-110287

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept